When MaRS Catalyst Fund considered investing in Flosonics Medical, we immediately saw the potential in its technology. A smart bandage that can non-invasively monitor arterial blood flow in critically ill patients has a large addressable market among emergency facilities and – crucially for us – could save lives and improve health outcomes.
One of Canada’s leading universities clearly agrees: Wilfrid Laurier has chosen Flosonics to be one of only 10 companies to join its Lazaridis Scale-Up Program.
The program, run by the university’s Lazaridis Institute for the Management of Technology Enterprises, supports a highly selected group of early-stage Canadian companies which it believes have potential to scale up globally.
It provides 120 hours of mentorship and strategic advice from leading entrepreneurs, including intensive weekend workshops in six different North American cities with experienced executives, with the aim of accelerating company growth and entering international markets.
MaRS Catalyst invested in Sudbury-based Flosonics as part of a $5 million seed-stage funding round in January, which is enabling the company to commercialize its first product, the FloPatch wearable sensor.
Its acceptance into the Wilfrid Laurier program is another sign that Flosonics is a company to watch.
Thumbnail image: Flosonics Medical